06.01.2017

Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference

 WALTHAM, Mass., January 6, 2017 — Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic medicines based on its proprietary mucus-penetrating particle (MPP) technology, announced today that Mark Iwicki, Chairman and Chief Executive Officer of Kala, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 11, 2017 at 4:00 PM PST. 

Mr. Iwicki commented, “Kala is currently conducting two parallel Phase 3 programs for our lead candidate, KPI-121, in dry eye disease, and a confirmatory Phase 3 trial for the treatment of inflammation and pain following cataract surgery. We are moving into a transformational period for our company with data expected from all three Phase 3 programs in 2017 and NDA filings are planned for late 2017 and early 2018. We are pleased with the opportunity to present at the J.P. Morgan Healthcare Conference and to educate new audiences about Kala.” 

About Kala Pharmaceuticals, Inc. 

Kala is a clinical stage pharmaceutical company focused on innovative treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic medicines with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. In addition to KPI-121, Kala is developing KPI-285, a novel RTKi, for back of the eye indications. Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications. 

Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, and is backed by leading life sciences investors including OrbiMed, RA Capital Management, Polaris Partners, Longitude Capital, Vivo Capital, Third Rock Ventures, CAM Capital, Lux Capital, CVF, LLC, and Ysios Capital. For more information, please visit Kala’s website at www.kalarx.com 

Contact: 

Kari Watson 

MacDougall Biomedical Communications 

(781) 235-3060 

kwatson@macbiocom.com 


Downloads

Download pdf English